Psyence Biomedical2024-04-12T12:23:19+02:00

Psyence Biomed

We develop market-leading clinical trails in the field of palliative care.  

Clinical trials

Psyence Biomedical Ltd is developing clinical trials in the field of palliative care. Our clinical trial program is focused on assessing the safety and efficacy of psilocybin-assisted therapy for the treatment of adjustment disorder in people with terminal diagnoses in comparison to psychotherapy alone. Adjustment disorder is an emotional or behavioural reaction to a stressful event in one’s life. We have partnered with leading psychedelic contract research organisation Ingenu to design and deliver our first clinical trial in Australia.

Psyence Biomed

We develop treatment protocols to treat mental health disorders with psilocybin in a clinical environment.

Clinical trials

Psyence Biomedical Ltd is developing clinical trials in the field of palliative care. Our clinical trial program is focused on assessing the safety and efficacy of psilocybin-assisted therapy for the treatment of adjustment disorder in people with terminal diagnoses in comparison to psychotherapy alone. Adjustment disorder is an emotional or behavioural reaction to a stressful event in one’s life. We have partnered with leading psychedelic contract research organisation Ingenu to design and deliver our first clinical trial in Australia.

Informed by nature
and guided by science

We develop treatment protocols to treat mental health disorders with psilocybin in a clinical environment.

Pioneering the use of natural

psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

Bringing together leaders in the business of medicine and science

Our team comprises experts in the development and commercialization of pharmaceutical products. We also have extensive experience in capital markets and business development, with a proven track record of creating shareholder value and achieving sustainable growth.

Our News

Our Global Footprint

Psyence is listed on the NASDAQ Stock Exchange (NASDAQ: PBM)

Our Global Footprint

Psyence is listed on the NASDAQ Stock Exchange (NASDAQ: PBM)

Our News

  • Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

April 9, 2024|

has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.

Go to Top